Tisagenlecleucel Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: CART-19, CART19, CTL019, CTL019 T-cells, KYMRIAH +2 more

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

Stanford University1
SWOG Cancer Research Network1

Indications

Cancer2
Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma1
Transformed Follic Lymph to Diff Large B-Cell Lymphoma1
Primary Mediastinal (Thymic) Large B-Cell Lymphoma1
Grade 3b Follicular Lymphoma1

Tucson, Arizona1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Palo Alto, California1 trial

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Stanford University

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.